John Frye
Impact in
- Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver physiology and pathology
-
- Thyroid Cancer Diagnosis and Treatment
Papers in
- Oncology 8
- Colorectal Cancer Treatments and Studies 3
- Pancreatic and Hepatic Oncology Research 3
- HER2/EGFR in Cancer Research 2
-
- Renal cell carcinoma treatment 3
- Co-authors
- Razelle Kurzrock (4 shared papers)Mark J. Ratain (4 shared papers)David S. Hong (4 shared papers)Ravi Salgia (4 shared papers)Linda Janisch (3 shared papers)Steven I. Sherman (2 shared papers)Ranee Mehra (1 shared paper)Robert F. Gagel (1 shared paper)
- Journals
- Journal of Clinical Oncology (6 papers)Cancer (2 papers)Journal of Cardiovascular Pharmacology (2 papers)Molecular Cancer Therapeutics (1 paper)Annals of Internal Medicine (1 paper)
- Partner nations
- United StatesNew ZealandSpain
In The Last Decade
John Frye
23 papers receiving 735 citations
John Frye's Hit Papers
Peers
Comparison fields: 5 of 77
- Hepatology 148
- Endocrinology, Diabetes and Metabolism 230
- Oncology 286
- Cancer Research 91
- Pathology and Forensic Medicine 101
Countries citing papers authored by John Frye
This map shows the geographic impact of John Frye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Frye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Frye more than expected).
Fields of papers citing papers by John Frye
This network shows the impact of papers produced by John Frye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Frye. The network helps show where John Frye may publish in the future.
Co-authors
The 25 scholars most cited alongside John Frye, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer Hit paper breakdown → | 2011 | 445 |
| 2 | 1995 | 63 | |
| 3 | 2008 | 63 | |
| 4 | 2021 | 22 | |
| 5 | 1989 | 21 | |
| 6 | 2008 | 20 | |
| 7 | 2002 | 18 | |
| 8 | 2019 | 15 | |
| 9 | 2008 | 15 | |
| 10 | 1993 | 12 | |
| 11 | 2020 | 9 | |
| 12 | A phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies | 2007 | 8 |
| 13 | 1989 | 8 | |
| 14 | 1992 | 7 | |
| 15 | 2016 | 6 | |
| 16 | 2019 | 5 | |
| 17 | 1989 | 5 | |
| 18 | Incorporating Quality Assurance in Pharmaceutical Compounding-related Courses in the PharmD Curricula. | 2020 | 4 |
| 19 | 2018 | 2 | |
| 20 | 1994 | 2 |
About John Frye
John Frye is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Cardiology and Cardiovascular Medicine and Hepatology, having authored 24 papers that have together received 754 indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (3 papers), Colorectal Cancer Treatments and Studies (3 papers), Cardiac Arrhythmias and Treatments (3 papers), Renal cell carcinoma treatment (3 papers), Cardiac electrophysiology and arrhythmias (3 papers), Pancreatic and Hepatic Oncology Research (3 papers), HER2/EGFR in Cancer Research (2 papers) and Ethics in medical practice (2 papers). The work is most often cited by research in Hepatology (148 citations), Endocrinology, Diabetes and Metabolism (230 citations), Oncology (286 citations), Cancer Research (91 citations) and Pathology and Forensic Medicine (101 citations). John Frye has collaborated with scholars based in United States, New Zealand and Spain. Frequent co-authors include Razelle Kurzrock, Mark J. Ratain, David S. Hong, Ravi Salgia, Linda Janisch, Steven I. Sherman, Ranee Mehra, Robert F. Gagel, Thomas Müller and David G. Pfister. Their work appears in journals such as Journal of Clinical Oncology, Cancer, Journal of Cardiovascular Pharmacology, Molecular Cancer Therapeutics and Annals of Internal Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.